Loading...
Indication – Sarcoma2024-06-04T09:58:57+01:00

Sarcoma

Established and novel chemo-free combinations in immuno-oncology

December 11th, 2021|

Immunotherapy was the major breakthrough in the treatment of lung cancer in the past years. The PD-1 inhibitor pembrolizumab is approved for the treatment of various tumor entities including advanced or metastatic non-small cell lung cancer (a/mNSCLC). Lenvatinib, a multikinase inhibitor and antineoplastic agent that is so far approved for certain solid tumors but not NSCLC, already showed promising antitumoral effects and a manageable safety profile when combined with pembrolizumab in a phase I/II trial.

Go to Top